Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols


  1. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Therapeutic advances in infectious disease. 2016;3(1):3-14.
  2. Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology. 2019;156(2):431-445.
  3. Mayo Clinic. Hepatitis C. Last updated 3/6/2018,. Accessed 5/9/2019. Published 2018. Accessed.
  4. McDonald JWD, Feagan BG. Evidence-Based Gastroenterology and Hepatology. Wiley; 2010.
  5. WHO. World Health Organization. What is hepatitis? Copyright 2019. Accessed 5/9/2019. Published 2019. Accessed.
  6. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171(3):242-248.
  7. CDC. Centers for Disease Control and Prevention. Hepatitis C Quesions and Answers for the Public: Transmission/Exposure. 11/2/2018. Accessed 5/9/2019. Published 2018. Accessed.
  8. Cavalheiro Nde P. Sexual transmission of hepatitis C. Revista do Instituto de Medicina Tropical de Sao Paulo. 2007;49(5):271-277.
  9. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. The American journal of gastroenterology. 2004;99(5):855-859.
  10. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis. 2008;198(5):683-686.
  11. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. PLoS One. 2011;6(3):e17781.
  12. Chakravarty D, Chakravarty DK, Lee WC. Liver Transplantation. Jaypee Brothers,Medical Publishers Pvt. Limited; 2010.
  13. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.
  14. Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M. Sherlock's diseases of the liver and biliary system. John Wiley & Sons; 2018.
  15. CDC. Hepatitis C Questions and Answers for Health Professionals. US HHS. Viral Hepatitis Web site. Published 2018. Accessed 01/30/2018.
  16. Sikorska K. The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals. Virulence. 2016;7(6):620-622.
  17. Cheifetz AS, Brown A, Curry M, Moss AC. Oxford American handbook of gastroenterology and hepatology. Oxford University Press; 2011.
  18. Hepatitis C Technical Advisory Group. United States Department of Veterans Affairs. Hepatitis C and Hepatocellular Carcinoma. Last updated 6/21/2005. Accessed 5/30/2012 Accessed.
  19. Angelico M. Epidemiology and outcome of hepatitis C relapse in transplant recipients. Transplantation proceedings. 2011;43(6):2457-2458.
  20. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2009;15(2):126-135.
  21. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2010;16(11):1228-1235.
  22. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Molecular medicine (Cambridge, Mass). 2007;13(1-2):97-104.
  23. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology (Baltimore, Md). 2008;48(5):1420-1429.
  24. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134(1):226-238.
  25. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest. 2007;117(7):1755-1758.
  26. Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51(5):845-852.
  27. Tsochatzis E, Papatheodoridis GV, Koliaraki V, et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. Journal of viral hepatitis. 2010;17(11):800-806.
  28. Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, Koike K. Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology. 2011;81 Suppl 1:11-17.
  29. Price L, Kowdley KV. The role of iron in the pathophysiology and treatment of chronic hepatitis C. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2009;23(12):822-828.
  30. Fujita N, Sugimoto R, Ma N, et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. Journal of viral hepatitis. 2008;15(7):498-507.
  31. Moriya K, Miyoshi H, Shinzawa S, et al. Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells. Journal of medical virology. 2010;82(5):776-792.
  32. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients. Intern Med. 2007;46(10):637-642.
  33. Sartori M, Andorno S, Rossini A, et al. A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C. European journal of gastroenterology & hepatology. 2011;23(12):1178-1184.
  34. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology (Baltimore, Md). 2000;32(1):135-138.
  35. Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int. 2007;27(2):268-273.
  36. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci. 2008;53(3):815-822.
  37. Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Journal of gastroenterology. 2007;42(10):830-836.
  38. Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. The American journal of gastroenterology. 2011;106(7):1255-1263.
  39. Echosens. Fibroscan 502 Touch. Accessed 5/31/2012. Published 2012. Accessed.
  40. Cales P. Presentation: Non-invasive evauation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C). Angers University, France. 3/21/2011. Accessed 5/31/2012 2011.
  41. Cales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie clinique et biologique. 2008;32(6 Suppl 1):40-51.
  42. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology (Baltimore, Md). 2012;55(1):58-67.
  43. Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y). 2011;7(7):445-454.
  44. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1970-1979, 1979.e1971-1973.
  45. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert review of molecular diagnostics. 2005;5(1):15-21.
  46. Grennan D. Treating Hepatitis C. JAMA. 2018;320(21):2280-2280.
  47. AASLD-IDSA HGP. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(10):1477-1492.
  48. Li J, Zhang T, Gordon SC, et al. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States. Journal of viral hepatitis. 2018;25(8):952-958.
  49. Gualerzi A, Bellan M, Smirne C, et al. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PloS one. 2018;13(12):e0209216-e0209216.
  50. Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology. 2018;2018:11.
  51. Kish T, Aziz A, Sorio M. Hepatitis C in a New Era: A Review of Current Therapies. P & T : a peer-reviewed journal for formulary management. 2017;42(5):316-329.
  52. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic ReviewOral Direct-Acting Agent Therapy for HCV Infection. Annals of Internal Medicine. 2017;166(9):637-648.
  53. Dhawan VK. Hepatitis C Medication. WebMD LLC. Medscape Gastroenterology Web site. Published 2019. Accessed 04/10/2019.
  54. Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatology International. 2018;12(3):214-222.
  55. Cacciatore I, Cornacchia C, Pinnen F, Mollica A, Di Stefano A. Prodrug approach for increasing cellular glutathione levels. Molecules (Basel, Switzerland). 2010;15(3):1242-1264.
  56. Tapryal N, Mukhopadhyay C, Mishra MK, Das D, Biswas S, Mukhopadhyay CK. Glutathione synthesis inhibitor butathione sulfoximine regulates ceruloplasmin by dual but opposite mechanism: Implication in hepatic iron overload. Free radical biology & medicine. 2010;48(11):1492-1500.
  57. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. The New England journal of medicine. 2011;365(19):1781-1789.
  58. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2008;14(1):25-30.
  59. Beloqui O, Prieto J, Suarez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. Journal of interferon research. 1993;13(4):279-282.
  60. Grant PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. Journal of medical virology. 2000;61(4):439-442.
  61. Gunduz H, Karabay O, Tamer A, Ozaras R, Mert A, Tabak OF. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9(12):2698-2700.
  62. Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Canadian family physician Medecin de famille canadien. 2011;57(6):659-663.
  63. Medici V, Virata MC, Peerson JM, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2011;35(11):1960-1965.
  64. Feld JJ, Modi AA, El-Diwany R, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. 2011;140(3):830-839.
  65. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One. 2010;5(11):e15492.
  66. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149-1160.
  67. Park KG, Min AK, Koh EH, et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology (Baltimore, Md). 2008;48(5):1477-1486.
  68. Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. Journal of clinical gastroenterology. 2005;39(8):737-742.
  69. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999;94 Suppl 3:84-89.
  70. Elattar G, Saleh Z, El-Shebini S, et al. The use of whey protein concentrate in management of chronic hepatitis C virus - a pilot study. Archives of medical science : AMS. 2010;6(5):748-755.
  71. Kume H, Okazaki K, Sasaki H. Hepatoprotective effects of whey protein on D-galactosamine-induced hepatitis and liver fibrosis in rats. Bioscience, biotechnology, and biochemistry. 2006;70(5):1281-1285.
  72. Khan MS, Dilawar S, Ali I, Rauf N. The possible role of selenium concentration in hepatitis B and C patients. Saudi J Gastroenterol. 2012;18(2):106-110.
  73. Rohr-Udilova N, Sieghart W, Eferl R, et al. Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology (Baltimore, Md). 2012;55(4):1112-1121.
  74. Himoto T, Yoneyama H, Kurokohchi K, et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res. 2011;31(11):829-835.
  75. Jones D, Hagen T, Weber R, Wierzbicka G, Bonkovsky H. Oral administration of glutathione (GSH) increases plasma GSH concentrations in humans. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1989;3:A1250.
  76. Hagen TM, Wierzbicka GT, Sillau AH, Bowman BB, Jones DP. Bioavailability of dietary glutathione: effect on plasma concentration. The American journal of physiology. 1990;259(4 Pt 1):G524-529.
  77. Kariya C, Leitner H, Min E, van Heeckeren C, van Heeckeren A, Day BJ. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am J Physiol Lung Cell Mol Physiol. 2007;292(6):L1590-1597.
  78. Aw TY, Wierzbicka G, Jones DP. Oral glutathione increases tissue glutathione in vivo. Chem Biol Interact. 1991;80(1):89-97.
  79. Iantomasi T, Favilli F, Marraccini P, Magaldi T, Bruni P, Vincenzini MT. Glutathione transport system in human small intestine epithelial cells. Biochim Biophys Acta. 1997;1330(2):274-283.
  80. Favilli F, Marraccini P, Iantomasi T, Vincenzini MT. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. The British journal of nutrition. 1997;78(2):293-300.
  81. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15(17):1956-1973.
  82. Ishii K, Takamura N, Shinohara M, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatology research : the official journal of the Japan Society of Hepatology. 2003;25(3):226-233.
  83. Kaito M, Iwasa M, Fujita N, et al. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. Journal of gastroenterology and hepatology. 2007;22(11):1894-1897.
  84. Ciesek S, von Hahn T, Colpitts CC, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (Baltimore, Md). 2011;54(6):1947-1955.
  85. Ma Q, Kim EY, Lindsay EA, Han O. Bioactive dietary polyphenols inhibit heme iron absorption in a dose-dependent manner in human intestinal Caco-2 cells. Journal of food science. 2011;76(5):H143-150.
  86. Saewong T, Ounjaijean S, Mundee Y, et al. Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Medicinal chemistry (Shariqah (United Arab Emirates)). 2010;6(2):57-64.
  87. Shawki A, Mackenzie B. Interaction of calcium with the human divalent metal-ion transporter-1. Biochemical and biophysical research communications. 2010;393(3):471-475.
  88. Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hulten L. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr. 1991;53(1):112-119.
  89. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132(5):1925-1936.
  90. Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int. 2009;29(3):366-373.
  91. Morishima C, Shuhart MC, Wang CC, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138(2):671-681, 681.e671-672.
  92. El-Lakkany NM, Hammam OA, El-Maadawy WH, Badawy AA, Ain-Shoka AA, Ebeid FA. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasites & vectors. 2012;5:9.
  93. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. Journal of viral hepatitis. 2005;12(6):559-567.
  94. Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (Baltimore, Md). 2010;51(6):1912-1921.
  95. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (Baltimore, Md). 2008;47(2):605-612.
  96. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50(4):434-449.
  97. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17(18):2288-2301.
  98. Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50(6):1102-1111.
  99. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138(3):1112-1122.
  100. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561-1567.
  101. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2007;5(4):408-416.
  102. Eurich D, Bahra M, Berg T, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2011;9(1):1-6.
  103. Rutter K, Scherzer TM, Beinhardt S, et al. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antiviral therapy. 2011;16(8):1327-1333.
  104. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52(6):951-952.
  105. Okiyama W, Tanaka N, Nakajima T, et al. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol. 2009;50(6):1236-1246.
  106. Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011;31(10):1432-1448.
  107. Lieber CS. Pathogenesis and treatment of alcoholic liver disease: progress over the last 50 years. Roczniki Akademii Medycznej w Bialymstoku (1995). 2005;50:7-20.
  108. Zhao QY, Wang HY, Zhang WX, Sun YL, Zheng Y. [Protective effect of polyenylphosphatidyl choline on liver in rat with sepsis]. Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue. 2011;23(7):401-404.
  109. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacological reports : PR. 2011;63(3):643-659.
  110. Azzam HS, Goertz C, Fritts M, Jonas WB. Natural products and chronic hepatitis C virus. Liver Int. 2007;27(1):17-25.
  111. Chien CF, Wu YT, Tsai TH. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed Chromatogr. 2011;25(1-2):21-38.
  112. Cyong JC, Ki SM, Iijima K, Kobayashi T, Furuya M. Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. The American journal of Chinese medicine. 2000;28(3-4):351-360.
  113. Wang R, Kong J, Wang D, Lien LL, Lien EJ. A survey of Chinese herbal ingredients with liver protection activities. Chinese medicine. 2007;2:5.
  114. Ashfaq UA, Masoud MS, Nawaz Z, Riazuddin S. Glycyrrhizin as antiviral agent against Hepatitis C Virus. Journal of translational medicine. 2011;9:112.
  115. Guyton KZ, Kensler TW. Prevention of liver cancer. Curr Oncol Rep. 2002;4(6):464-470.
  116. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:94-100.
  117. Schrofelbauer B, Raffetseder J, Hauner M, Wolkerstorfer A, Ernst W, Szolar OH. Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signalling. Biochem J. 2009;421(3):473-482.
  118. Li XL, Zhou AG, Zhang L, Chen WJ. Antioxidant status and immune activity of glycyrrhizin in allergic rhinitis mice. International journal of molecular sciences. 2011;12(2):905-916.
  119. Gomez EV, Perez YM, Sanchez HV, et al. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol. 2010;16(21):2638-2647.
  120. Vilar Gomez E, Sanchez Rodriguez Y, Torres Gonzalez A, et al. Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. BMJ open. 2011;1(2):e000140.
  121. Korenaga M, Hidaka I, Nishina S, et al. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice. Liver Int. 2011;31(4):552-560.
  122. Hidaka I, Hino K, Korenaga M, et al. Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein. Liver Int. 2007;27(6):845-853.
  123. Nielsen ML, Pareek M, Andersen I. [Liquorice-induced hypertension and hypokalaemia]. Ugeskrift for laeger. 2012;174(15):1024-1025.
  124. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55(9):2624-2628.
  125. Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md). 2010;51(4):1158-1167.
  126. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol. 2011;17(47):5184-5190.
  127. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol. 2012;18(8):800-805.
  128. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1961-1969.
  129. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (Baltimore, Md). 2010;51(1):201-209.
  130. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166(11):1190-1195.
  131. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007;132(5):1740-1745.
  132. Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (Baltimore, Md). 2007;46(2):430-435.
  133. Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (Baltimore, Md). 2009;50(5):1360-1369.
  134. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005;128(1):24-32.
  135. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology. 2005;129(6):1928-1936.
  136. Wang GF, Shi LP, Ren YD, et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral research. 2009;83(2):186-190.
  137. Yuasa K, Naganuma A, Sato K, et al. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int. 2006;26(9):1111-1118.
  138. Takagi H, Nagamine T, Abe T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. Journal of viral hepatitis. 2001;8(5):367-371.
  139. Ko WS, Guo CH, Hsu GS, Chiou YL, Yeh MS, Yaun SR. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Clin Biochem. 2005;38(7):614-620.
  140. Murakami Y, Koyabu T, Kawashima A, et al. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr Sci Vitaminol (Tokyo). 2007;53(3):213-218.
  141. Matsuoka S, Matsumura H, Nakamura H, et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. Journal of clinical biochemistry and nutrition. 2009;45(3):292-303.
  142. Himoto T, Hosomi N, Nakai S, et al. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scandinavian journal of gastroenterology. 2007;42(9):1078-1087.
  143. Suzuki H, Takagi H, Sohara N, et al. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial. World J Gastroenterol. 2006;12(8):1265-1269.
  144. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer research. 2003;23(1a):363-398.
  145. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochemical pharmacology. 2006;72(11):1439-1452.
  146. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1-75.
  147. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A. 1993;90(5):1839-1842.
  148. Chen D-Y, Shien J-H, Tiley L, et al. Curcumin inhibits influenza virus infection and haemagglutination activity. Food Chemistry. 2010;119(4):1346-1351.
  149. Si X, Wang Y, Wong J, Zhang J, McManus BM, Luo H. Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J Virol. 2007;81(7):3142-3150.
  150. Kim K, Kim KH, Kim HY, Cho HK, Sakamoto N, Cheong J. Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. FEBS letters. 2010;584(4):707-712.
  151. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Current pharmaceutical biotechnology. 2012;13(1):218-228.
  152. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. European journal of pharmacology. 2008;585(2-3):325-337.
  153. Gonzalez O, Fontanes V, Raychaudhuri S, et al. The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology (Baltimore, Md). 2009;50(6):1756-1764.
  154. Bachmetov L, Gal-Tanamy M, Shapira A, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. Journal of viral hepatitis. 2012;19(2):e81-88.
  155. Malaguarnera M, Vacante M, Giordano M, et al. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-alpha 2b plus ribavirin. World J Gastroenterol. 2011;17(39):4414-4420.
  156. Malaguarnera M, Vacante M, Bertino G, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2011;31(9):653-659.